Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Collegium Pharmaceutical, Inc. stands tenth among them.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is strengthening its position as a leader in responsible pain management and ADHD treatment, which is driven by new clinical research and market growth in 2025. The company has built a diverse portfolio addressing chronic pain and attention disorders, and recent initiatives highlight its commitment to evidence-based innovation.

A major development this year is Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s plan to present nine real-world data posters from its pain management portfolio at PAINWeek 2025 in Las Vegas. These presentations, scheduled for September, will provide fresh insights into the use and effectiveness of products such as BELBUCA, Xtampza ER, and the Nucynta franchise. By sharing real-world evidence, the business is reinforcing its focus on clinical transparency and patient-centered outcomes, while supporting healthcare providers with data to guide treatment decisions.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s financial performance further reflects its momentum, solidifying its place among the best pharmaceutical stocks to watch in 2025. In the second quarter of 2025, the corporation reported record pain portfolio revenues of $155.4 million, with all three core products showing year-over-year growth. Alongside this, its ADHD therapy Jornay PM, acquired through the 2024 purchase of Ironshore Therapeutics, has emerged as a major growth driver, with prescriptions climbing 23% and prescriber reach at an all-time high.

While we acknowledge the potential of COLL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.